These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 28100427)

  • 21. Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes.
    Brady WJ; DeBehnke DJ; Laundrie D
    Acad Emerg Med; 1999 Jun; 6(6):609-17. PubMed ID: 10386678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.
    Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM
    J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrocardiographic measures of repolarization heterogeneity are not predictive for Torsades de Pointes among undifferentiated patients with prolonged QTc: A case control study.
    Marill KA; Lopez S; Hark D; Spahr J; Shesh-Muthal K; Xue J; Rowlandson GI; Liu SW
    J Cardiovasc Electrophysiol; 2023 Jan; 34(1):166-176. PubMed ID: 36335640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
    Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
    J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
    Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
    J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global electrical heterogeneity associated with drug-induced torsades de pointes.
    Stabenau HF; Shen C; Zimetbaum P; Buxton AE; Tereshchenko LG; Waks JW
    Heart Rhythm; 2021 Jan; 18(1):57-62. PubMed ID: 32781158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
    Jardin CG; Putney D; Michaud S
    Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased ventricular ectopy precedes Torsades de Pointes in patients with prolonged QT.
    Marill KA; Lopez S; Hark D; Spahr J; Kapadia N; Liu SW
    J Electrocardiol; 2023; 80():17-23. PubMed ID: 37105125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes.
    Lazzerini PE; Laghi-Pasini F; Bertolozzi I; Morozzi G; Lorenzini S; Simpatico A; Selvi E; Bacarelli MR; Finizola F; Vanni F; Lazaro D; Aromolaran A; El Sherif N; Boutjdir M; Capecchi PL
    Heart; 2017 Nov; 103(22):1821-1829. PubMed ID: 28490617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
    Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
    J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
    Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
    J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology.
    Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C
    Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs.
    Thomsen MB; Verduyn SC; Stengl M; Beekman JD; de Pater G; van Opstal J; Volders PG; Vos MA
    Circulation; 2004 Oct; 110(16):2453-9. PubMed ID: 15477402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged QT interval by methadone: relevance for daily practice? A prospective study in patients with cancer and noncancer pain.
    van den Beuken-van Everdingen MH; Geurts JW; Patijn J
    J Opioid Manag; 2013; 9(4):263-7. PubMed ID: 24353019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.